Alexander T Cohen

3.5k total citations · 3 hit papers
19 papers, 2.6k citations indexed

About

Alexander T Cohen is a scholar working on Internal Medicine, Cardiology and Cardiovascular Medicine and Hematology. According to data from OpenAlex, Alexander T Cohen has authored 19 papers receiving a total of 2.6k indexed citations (citations by other indexed papers that have themselves been cited), including 18 papers in Internal Medicine, 16 papers in Cardiology and Cardiovascular Medicine and 5 papers in Hematology. Recurrent topics in Alexander T Cohen's work include Venous Thromboembolism Diagnosis and Management (18 papers), Atrial Fibrillation Management and Outcomes (11 papers) and Acute Myocardial Infarction Research (10 papers). Alexander T Cohen is often cited by papers focused on Venous Thromboembolism Diagnosis and Management (18 papers), Atrial Fibrillation Management and Outcomes (11 papers) and Acute Myocardial Infarction Research (10 papers). Alexander T Cohen collaborates with scholars based in Canada, United States and United Kingdom. Alexander T Cohen's co-authors include Alain Leizorovicz, Samuel Z. Goldhaber, Carl‐Gustav Olsson, Alexander G.G. Turpie, Paul T. Vaitkus, Alexander G.G. Turpie, Bruce L. Davidson, Martin H. Prins, Witold Tomkowski and Michael R. Lassen and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Circulation.

In The Last Decade

Alexander T Cohen

19 papers receiving 2.5k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients

2004 735 citations Alain Leizorovicz, Alexander T Cohen et al. Circulation profile →
Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial

2006 628 citations Alexander T Cohen, Bruce L. Davidson et al. BMJ profile →
Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients

2013 436 citations Alexander T Cohen, Theodore E. Spiro et al. New England Journal of Medicine profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Alexander T Cohen Canada	10	2.3k	1.9k	558	518	314	19	2.6k
Alexander G.G. Turpie Canada	15	2.1k 0.9×	1.6k 0.9×	591 1.1×	441 0.9×	316 1.0×	25	2.3k
Aneel A. Ashrani United States	28	1.8k 0.8×	1.2k 0.6×	741 1.3×	576 1.1×	500 1.6×	102	2.5k
Carl‐Gustav Olsson Sweden	16	2.9k 1.2×	2.0k 1.0×	797 1.4×	709 1.4×	446 1.4×	22	3.2k
Raza Alikhan United Kingdom	20	1.4k 0.6×	1.0k 0.5×	538 1.0×	322 0.6×	483 1.5×	57	2.3k
Paul L. den Exter Netherlands	25	2.0k 0.9×	1.3k 0.7×	452 0.8×	442 0.9×	237 0.8×	71	2.4k
Louis Desjardins Canada	13	3.5k 1.5×	2.4k 1.3×	1.4k 2.4×	846 1.6×	534 1.7×	20	3.9k
Arina J. ten Cate‐Hoek Netherlands	27	1.5k 0.6×	856 0.5×	1.0k 1.8×	427 0.8×	373 1.2×	110	2.2k
Jean‐Yves Darmon France	9	1.6k 0.7×	1.2k 0.6×	468 0.8×	312 0.6×	398 1.3×	11	2.0k
Lisa Baumann Kreuziger United States	23	1.1k 0.5×	708 0.4×	568 1.0×	266 0.5×	340 1.1×	76	1.8k
Janis Bormanis Canada	14	1.7k 0.7×	815 0.4×	679 1.2×	430 0.8×	329 1.0×	34	2.2k

Countries citing papers authored by Alexander T Cohen

Since Specialization

Citations

This map shows the geographic impact of Alexander T Cohen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Alexander T Cohen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Alexander T Cohen more than expected).

Fields of papers citing papers by Alexander T Cohen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Alexander T Cohen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Alexander T Cohen. The network helps show where Alexander T Cohen may publish in the future.

Co-authorship network of co-authors of Alexander T Cohen

This figure shows the co-authorship network connecting the top 25 collaborators of Alexander T Cohen. A scholar is included among the top collaborators of Alexander T Cohen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Alexander T Cohen. Alexander T Cohen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Gal, Grégoire Le, Giancarlo Agnelli, Harald Darius, et al.. (2023). Event rates and risk factors for venous thromboembolism and major bleeding in a population of hospitalized adult patients with acute medical illness receiving enoxaparin thromboprophylaxis. European Journal of Internal Medicine. 121. 48–55. 3 indexed citations

Martin, Anne‐Céline, Wei Huang, Samuel Z. Goldhaber, et al.. (2019). Estimation of Acutely Ill Medical Patients at Venous Thromboembolism Risk Eligible for Extended Thromboprophylaxis Using APEX Criteria in US Hospitals. Clinical and Applied Thrombosis/Hemostasis. 25. 2873278536–2873278536. 7 indexed citations

Chi, Gerald, C. Michael Gibson, Adrian F. Hernandez, et al.. (2018). 4321Betrixaban versus enoxaparin for venous thromboembolism prophylaxis in critically ill patients: findings from the APEX trial. European Heart Journal. 39(suppl_1). 1 indexed citations

Chi, Gerald, Tarek Nafee, Samuel Z. Goldhaber, et al.. (2017). Abstract 20322: Extended-Duration Betrixaban Reduces the Risk of Venous Thromboembolism-Related Rehospitalization Among Acutely Ill Hospitalized Medical Patients: An APEX Trial Substudy. Circulation. 1 indexed citations

Gibson, C. Michael, Tarek Nafee, Samuel Z. Goldhaber, et al.. (2017). Abstract 20393: Full-Dose Betrixaban Reduces Venous Thromboembolism-Related Mortality: An APEX Trial Substudy. Circulation. 2 indexed citations

Gibson, C. Michael, Douglas Arbetter, Purva Jain, et al.. (2017). P1732Extended duration betrixaban in acutely ill medical patients is associated with reduction in fatal or irreversible ischemic or bleeding events compared with standard dose enoxaparin: an APEX substudy. European Heart Journal. 38(suppl_1). 1 indexed citations

Gibson, C. Michael, Gerald Chi, Rim Halaby, et al.. (2016). Extended-Duration Betrixaban Reduces the Risk of Stroke Versus Standard-Dose Enoxaparin Among Hospitalized Medically Ill Patients. Circulation. 135(7). 648–655. 50 indexed citations

Jain, Purva, Donald Szlosek, Serge Korjian, et al.. (2016). Abstract 19325: Betrixaban Reduces the Burden of Multiple Symptomatic Venous Thromboembolic Events in the APEX Trial. 134. 2 indexed citations

Korjian, Serge, Yazan Daaboul, Rim Halaby, et al.. (2015). Extended-Duration Thromboprophylaxis Among Acute Medically Ill Patients. Journal of Cardiovascular Pharmacology and Therapeutics. 21(3). 227–232. 8 indexed citations

10.

Cohen, Alexander T, Robert A. Harrington, Samuel Z. Goldhaber, et al.. (2013). The design and rationale for the Acute Medically Ill Venous Thromboembolism Prevention with Extended Duration Betrixaban (APEX) study. American Heart Journal. 167(3). 335–341. 71 indexed citations

11.

Cohen, Alexander T, Theodore E. Spiro, Harry R. Büller, et al.. (2013). Rivaroxaban for Thromboprophylaxis in Acutely Ill Medical Patients. New England Journal of Medicine. 368(6). 513–523. 436 indexed citations breakdown →

12.

Kakkar, Ajay K., Alexander T Cohen, Victor F. Tapson, et al.. (2010). Venous Thromboembolism Risk and Prophylaxis in the Acute Care Hospital Setting (ENDORSE Survey). Annals of Surgery. 251(2). 330–338. 82 indexed citations

13.

Bousser, Marie‐Germaine, H.R. Büller, Alexander T Cohen, et al.. (2008). Comparison of idraparinux with vitamin K antagonists for prevention of thromboembolism in patients with atrial fibrillation: a randomised, open-label, non-inferiority trial. The Lancet. 371(9609). 315–321. 199 indexed citations

14.

Cohen, Alexander T, Bruce L. Davidson, Alexander Gallus, et al.. (2006). Efficacy and safety of fondaparinux for the prevention of venous thromboembolism in older acute medical patients: randomised placebo controlled trial. BMJ. 332(7537). 325–329. 628 indexed citations breakdown →

15.

Yavin, Yshai, et al.. (2005). Pharmacological Prevention of Venous Thromboembolism in Medical Patients at Risk. American Journal of Cardiovascular Drugs. 5(6). 409–415. 5 indexed citations

16.

Leizorovicz, Alain, Alexander G.G. Turpie, Alexander T Cohen, et al.. (2004). Epidemiology of venous thromboembolism in Asian patients undergoing major orthopedic surgery without thromboprophylaxis. The SMART Study. Journal of Thrombosis and Haemostasis. 3(1). 28–34. 130 indexed citations

17.

Leizorovicz, Alain, Alexander T Cohen, Alexander G.G. Turpie, et al.. (2004). Randomized, Placebo-Controlled Trial of Dalteparin for the Prevention of Venous Thromboembolism in Acutely Ill Medical Patients. Circulation. 110(7). 874–879. 735 indexed citations breakdown →

18.

Alikhan, Raza, Alexander T Cohen, S. Combe, et al.. (2003). Prevention of venous thromboembolism in medical patients with enoxaparin. Blood Coagulation & Fibrinolysis. 14(4). 341–346. 189 indexed citations

19.

Cohen, Alexander T & Raza Alikhan. (2001). Prophylaxis of venous thromboembolism in medical patients. Current Opinion in Pulmonary Medicine. 7(5). 332–337. 24 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact